Dr. Lipson is an internationally-recognized skin cancer and immunotherapy specialist at Johns Hopkins. He received his medical degree in 2005 from the Mount Sinai School of Medicine in New York City, where he graduated with distinction in research. He completed his internship and residency in Internal Medicine at The Johns Hopkins Hospital, and completed a Medical Oncology fellowship at the Johns Hopkins Kimmel Cancer Center. Dr. Lipson leads cutting edge clinical trials for patients with melanoma and other skin cancers. As a member of the Johns Hopkins Melanoma and Cancer Immunology Programs, he focuses on evaluating novel therapies for patients with high-risk or advanced disease. Dr. Lipson’s publications include the first reports of organ transplant recipients treated with immune checkpoint inhibitors for advanced cancer, and the first description of kidney retransplantation performed after immunotherapy–related organ rejection. Based on his published work, Dr. Lipson initiated a clinical trial testing a novel combination of immune-based therapies for kidney transplant recipients with advanced selected cancers. Results from this trial - the first of its kind - were reported in 2022 at an international oncology meeting. Dr. Lipson is a leader in the clinical development of relatlimab, an antibody blocking the LAG-3 immune checkpoint. He leads a phase 2 trial testing combination immune checkpoint inhibitor therapy—including anti-LAG-3—for patients with advanced basal cell carcinoma. In June 2021, Dr. Lipson presented findings from the first phase 3 study establishing the LAG-3 pathway as the third immune checkpoint pathway in history, after CTLA-4 and PD-1, for which blockade has clinical benefit. This trial supported the FDA's approval of a new therapy for patients with advanced melanoma. In addition to his research activities, Dr. Lipson is an educator in the field of cancer immunotherapy. Many of his lectures focus on the management of immune-mediated drug toxicities associated with novel cancer drugs. Dr. Lipson conducts regular clinical practices in Baltimore, Maryland and at Sibley Memorial Hospital in Washington, D.C. as part of the multidisciplinary Melanoma Program at Johns Hopkins. Dr. Lipson is rated as an Elite provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Melanoma of the Eye, Metastatic Uveal Melanoma, and Pancreaticoduodenectomy.

Dr. Julie Lange is an assistant professor of surgery, dermatology and oncology at the Johns Hopkins University School of Medicine. Dr. Lange was one of the original members of the Johns Hopkins melanoma group when it was first formed in 1995 and now serves as a clinical co-director of the Melanoma Program. Dr. Lange introduced the sentinel node technique to Johns Hopkins for both melanoma and breast cancer in the 1990s and has extensive experience with this technique. Dr. Lange is a graduate of the Vanderbilt University School of Medicine and completed her general surgery training at Yale-New Haven Hospital. She completed a fellowship in surgical oncology and immunotherapy at the Surgery Branch of the National Cancer Institute as well. Dr. Lange joined the faculty of the Department of Surgery at Johns Hopkins in 1994 and subsequently earned a Sc.M. in clinical investigation at the Johns Hopkins Bloomberg School of Public Health. She has particular interest in melanoma at extremes of age, and in the factors associated with variance in melanoma care. Dr. Lange has published the largest study of melanoma in children, adolescents and young adults. She recognizes that melanoma in the older patient is a growing epidemic and has investigated the socioeconomic, demographic and healthcare factors that influence the treatment of melanoma in older persons. Dr. Lange is a member of the melanoma panel of the National Comprehensive Cancer Network, a group that annually evaluates and revises national treatment guidelines for melanoma. In 2015, she was inducted for her work into the Miller-Coulson Academy of Clinical Excellence, which recognizes outstanding clinicians at Johns Hopkins based on a number of factors, including communication and interpersonal skills, professionalism and humanism, a scholarly approach to clinical practice, and a passion for patient care. Dr. Lange is rated as a Distinguished provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Melanoma, Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Lymphadenectomy.

Dr. Jihad Mohamad Alhariri is an assistant professor of dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include dermatology and medical dermatology. Dr. Alhariri received his undergraduate degree from the American University of Beirut. He earned his M.D. from the American University of Beirut and his M.P.H. from the Johns Hopkins University School of Public Health. He completed a residency in internal medicine at Good Samaritan Hospital of Maryland and a residency in dermatology at Johns Hopkins. Dr. Alhariri is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Hidradenitis Suppurativa, Giant Congenital Melanocytic Nevus, and Giant Congenital Nevus.

Dr. Kleinberg specializes in the radiation treatments, including stereotactic radiosurgery, of brain and spinal tumors. Areas of research include both tumors arising in the central nervous system and tumors metastasizing from other locations. He also specializes in the treatment of esophageal tumors and has led national clinical trials in both therapy of brain tumors as well as esophageal cancer. Dr. Kleinberg has been recently named in the US News and World Report list of top 1% of doctors in his specialty. He is the co-chair of the Eastern Cooperative Oncology Group Brain Tumor Working Group, Vice-Chair of the NCI Cooperative Group Steering Committee for Esophageal and Gastric Tumors, and is a member of the NCI Cooperative Group Steering Committee for Gastrointestinal Tumors. He is also on the American College of Radiation Oncology Neurologic Cancer Practice Accreditation Team. Make A Gift. Dr. Kleinberg is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Glioblastoma, Astrocytoma, Brain Tumor, Hepato-Pancreato-Biliary Surgery, and Gamma Knife Radiosurgery.

Petr Hausner is an Oncologist and a Hematologist in Baltimore, Maryland. Dr. Hausner is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Pseudomyxoma Peritonei, Colorectal Cancer, Familial Colorectal Cancer, and Anal Cancer. Dr. Hausner is currently accepting new patients.

Dr. Janis Taube is a professor of dermatology and pathology at the Johns Hopkins University School of Medicine and a member of the Johns Hopkins Kimmel Cancer Center. Her area of clinical expertise is dermatopathology. Dr. Taube serves as the Director of the Division of Dermatopathology and as the Assistant Director of the Dermatoimmunology Laboratory at the School of Medicine. Dr. Taube received her undergraduate degree in engineering from Duke University. She earned her M.D. from Tulane University and her M.Sc. in molecular medicine from University College London. She completed her residency in pathology at Johns Hopkins where she also served as the chief resident, before undertaking a dermatopathology fellowship at Stanford University. In 2009, Dr. Taube returned to Johns Hopkins for her certification in the Melanoma Clinic. She is one of the lead scientific researchers in the Department of Dermatology at Johns Hopkins. She has written over 180 peer-reviewed publications, and her research has been cited over 70,000 times. In addition to running her own research laboratory, she serves as the co-Director of the Mark Foundation Center for Advanced Genomics and Imaging and also as the co-Director of the Tumor Microenvironment Core Laboratory for the Bloomberg~Kimmel Institute for Cancer Immunotherapy. Dr. Taube is rated as a Distinguished provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Melanoma, Merkel Cell Carcinoma, Basal Cell Skin Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), and Pancreaticoduodenectomy.

Dr. Topalian is a physician-scientist whose studies of anti-tumor immunity have been foundational in developing cancer immunotherapy. She has published over 160 original research articles and reviews in this area and is one of the most highly cited researchers in the biomedical field. She received her medical and scientific training at Tufts University School of Medicine, Thomas Jefferson University Hospital, Children’s Hospital of Philadelphia and the National Cancer Institute. She joined the Johns Hopkins Kimmel Cancer Center in 2006 as the inaugural director of its Melanoma Program. Dr. Topalian is credited with advancing the clinical development of anti-PD-1 immunotherapy, and her work is widely recognized. She was named one of Nature’s 10 in 2014, and received the Karnofsky Award from ASCO in 2015, the Taubman Prize in 2016, the NCI’s Rosalind E. Franklin Award in 2018, the American Academy of Dermatology’s Gruber Memorial Cancer Research Award in 2020, and the Award for Distinguished Research in the Biomedical Sciences from the Association of American Medical Colleges in 2021 for landmark discoveries in cancer immunotherapy. Dr. Topalian was elected to the National Academy of Medicine in 2017, and to the American Association for Cancer Research Academy in 2022. Her work has opened new avenues of scientific investigation and established immunotherapy as a pillar of oncology. Dr. Topalian is rated as a Distinguished provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Merkel Cell Carcinoma, Melanoma, Neuroendocrine Tumor, and Anal Cancer.

Dr. Sewon Kang is the Noxell Professor and Chairman of the Department of Dermatology at the Johns Hopkins University School of Medicine and the Dermatologist-in-Chief of Johns Hopkins Hospital. He is also founder and co-Director of the Cutaneous Translational Research Program (CTReP) at Hopkins. A recipient of the Dermatology Foundation's Career Development Award, he has received other research awards and grants from the American Dermatological Association, the National Psoriasis Foundation and the National Institutes of Health (Roadmap T32, K24, and R01). His research focus has been in the areas of skin pharmacology and photomedicine. He is the Past President of the Photomedicine Society, and the American Acne and Rosacea Society. Dr. Kang is or has been on the Board of Directors of multiple organizations including, the Society for Investigative Dermatology, the Association of Professors of Dermatology, the Dermatology Foundation, and the Skin of Color Society. An author on over 240 publications and book chapters, Dr. Kang is also the Editor-in-Chief of the 9th edition of the Fitzpatrick's Dermatology textbook. He is an inventor/co-inventor of 17 patents and has given over 300 presentations globally. A graduate with honors from Williams College and the University of Michigan, Dr. Kang completed dermatology residency and fellowship at the Harvard Medical School/Massachusetts General Hospital. He sees patients exclusively at the Johns Hopkins Hospital, and his areas of clinical expertise include photomedicine, skin cancer (melanoma), skin aging, and dermatology for ethnic skin. Dr. Kang is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Acne, Prurigo Nodularis, and Rosacea.

Maie John is an Otolaryngologist in Baltimore, Maryland. Dr. John is rated as a Distinguished provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Tongue Cancer, Melanoma, Glossectomy, and Gastrostomy.

Julie R. Brahmer, M.D., M.Sc. is the Director of the Thoracic Oncology Program, Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the Marilyn Meyerhoff Professor in Thoracic Oncology. She also directs the Kimmel Cancer Center on the Johns Hopkins Bayview campus and is co-principal investigator on Johns Hopkins' National Clinical Trials Network. Dr. Brahmer received her undergraduate degree in Chemistry and Philosophy in 1989 from the Creighton University in Omaha, Nebraska and went on to receive her medical degree from the University of Nebraska Medical Center College of Medicine in 1993. Completing her internship and residency in Internal Medicine at the University of Utah, Dr. Brahmer later became the Chief Medical Resident until moving to Baltimore to complete her fellowship in Medical Oncology at the Kimmel Cancer Center at Johns Hopkins. Dr. Brahmer is an active clinical leader in the treatment of lung cancer and mesothelioma. She leads the organization of the multidisciplinary thoracic malignancy conference whose members meet weekly to discuss thoracic malignancy cases that need a multidisciplinary review/approach. Dr. Brahmer's research and clinical practice focuses on the development of new therapies for the treatment and prevention of lung cancer and mesothelioma. Dr. Brahmer's research interests include leading early phase immunotherapy trials of anti-PD-1 antibodies, international phase III studies of immunotherapies in lung cancer and investigator-initiated trials evaluating epigenetic therapies in combination with immunotherapies. She is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group (ECOG) Thoracic Committee and Cancer Prevention Steering Committee. She is one of the founding Board members for the National Lung Cancer Partnership (formerly Women Against Lung Cancer). Within the National Lung Cancer Partnership, she currently serves as a member and the Chairman of the Scientific Executive Committee. She is also on the medical advisory board of the Lung Cancer Research Fund and the Mesothelioma Applied Research Foundation. Dr. Brahmer is rated as a Distinguished provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC).

Dr. William H. Sharfman is an associate professor of oncology and dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include cutaneous oncology, dermatology and immunotherapy. He helped create the well-established Melanoma Program at the Johns Hopkins Kimmel Cancer Center in 1994. Dr. Sharfman serves as the director of cutaneous oncology and clinical co-director for oncology at the Johns Hopkins Melanoma Program. He earned his M.D. from the University of Toledo College of Medicine. He completed his residency at Cleveland Clinic and performed a fellowship in hematology and oncology at Cleveland Clinic. Dr. Sharfman's research interests include novel therapies for high risk and advanced melanoma patients. Dr. Sharfman is rated as an Elite provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Eccrine Porocarcinoma, and Familial Pancreatic Cancer.

Akila Viswanathan, M.D., M.P.H., is the director for the Department of Radiation Oncology and Molecular Radiation Sciences, and a professor of radiation oncology, gynecology/obstetrics and oncology for Johns Hopkins University School of Medicine. Dr. Viswanathan leads the department emphasizing excellence in clinical care, research and education. She has expertise with gynecologic cancers and their treatment, including cervical and uterine cancers and image-guided brachytherapy. She has developed numerous clinical innovations and initiated several system-wide integration efforts at all sites, including Green Spring Station, Bayview, Johns Hopkins Hospital, Suburban's Rockledge site, and Sibley Memorial Hospital for the Johns Hopkins Department of Radiation Oncology. Dr. Viswanathan earned her undergraduate degree at Harvard University, her medical degree at the University of Pittsburgh School of Medicine, followed by her Masters in Public Health and Masters in Epidemiology at the Harvard School of Public Health. She completed a residency in radiation oncology at the Joint Center for Radiation Therapy at Harvard Medical School, where she served as chief resident. She has had research grant funding through the National Cancer Institute K07, R21 and R01 programs to support efforts in gynecologic cancers, specifically looking at the identification of gynecologic tumors at the time of brachytherapy under magnetic resonance imaging. The research team has developed several novel clinical innovations. Dr. Viswanathan has been named one of America's Top Doctors by Newsweek, Who’s who in America, and a Super Doctor by the Washington Post magazine. Dr. Viswanathan served as President and Chair of the Board of the American Brachytherapy Society; Chair of Education Committee for American Society for Radiation Oncology; and, on the Gynecologic Cancer Steering Committee and the uterine cancer task force for the National Cancer Institute. Dr. Akila Viswanathan has published more than 200 articles and chapters, and lectures nationally and internationally. She is the Editor-in-Chief for Seminars in Radiation Oncology. She is on the editorial board of Gynecologic Oncology and Brachytherapy, and is an editor of several textbooks including Gynecologic Radiation Therapy: Novel Approaches to Image-Guidance and Management, Radiation Therapy Techniques for Gynecologic Cancers, and Gunderson and Tepper's Clinical Radiation Oncology. Make A Gift. Dr. Viswanathan is rated as an Advanced provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Vaginal Cancer, Cervical Cancer, Vulvar Cancer, Vulvectomy, and Cordotomy.

Dr. Rebecca Stone is an associate professor in the Johns Hopkins Medicine Department of Gynecology and Obstetrics. Her area of clinical expertise is gynecologic cancers, including cervical, uterine, vulvar and ovarian cancer, as well as gestational trophoblastic disease. Dr. Stone is a highly skilled surgeon with expertise in laparoscopic and robotic surgery for gynecologic tumors. She also serves as director of the Gynecology Enhanced Recovery after Surgery initiative, an innovative, multidisciplinary program that improves recovery and healing time after major abdominal surgery, as well as minimizes health care costs for patients. Dr. Stone received her undergraduate degree in biology from the University of Virginia. She earned her medical degree from the University of Virginia School of Medicine, where she subsequently completed her residency in obstetrics and gynecology. Dr. Stone performed a four-year gynecologic oncology fellowship at the University of Texas MD Anderson Cancer Center. She also earned a master’s degree in cancer biology from the University of Texas in 2010. Prior to joining Johns Hopkins, Dr. Stone was an assistant professor at the University of Arkansas for Medical Sciences, where she was one of five gynecologic oncologists serving the entire state. Dr. Stone is internationally recognized for her research pertaining to early diagnosis and treatment of ovarian cancer. She is widely published in the field of gynecologic oncology, with first-author papers in the New England Journal of Medicine and Lancet Oncology, as well as over 40 co-authored manuscripts in peer-reviewed medical journals. She was honored with an award for one of the most influential papers published in the field of obstetrics and gynecology in 2012 and with an Ovarian Cancer Research Fund Grant for “Unplugging Ovarian Cancer from the Power of Platelets.” Dr. Stone strongly believes in a multidisciplinary team approach to gynecologic cancer care. She seeks to provide women with the most advanced and personalized treatment plans while best preserving quality of life. She enjoys working with community providers so that patients are comforted by receiving care close to home. Dr. Stone is rated as an Advanced provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Hysterectomy, and Oophorectomy.

James Stuart Ferriss is an associate professor in the Johns Hopkins Department of Gynecology and Obstetrics and director of the F.J. Montz Gynecologic Oncology Fellowship Program. He is an expert in the care of women with cancers of the uterus, cervix, vulva, vagina, fallopian tubes and ovaries. Dr. Ferriss is passionate about minimally invasive approaches to surgery and has extensive experience with robotic surgery. Dr. Ferriss received his undergraduate and medical degrees from Louisiana State University. He then completed his residency in obstetrics and gynecology at the University of Texas Southwestern Medical Center and his fellowship in gynecologic oncology at the University of Virginia. Prior to joining Johns Hopkins, Dr. Ferriss was associate professor in the departments of women’s health and oncology at the University of Texas at Austin Dell Medical School. Before that, he was assistant professor in the department of obstetrics, gynecology and reproductive sciences at Temple University in Philadelphia. Dr. Ferriss’ research is focused on innovations in surgical and clinical education. Dr. Ferriss serves on a variety of boards and is a member of the Society of Gyneocologic Oncology, Mid-Atlantic Gynecologic Oncology Society, American Society of Clinical Oncology, the American College of Surgeons and the American Congress of Obstetricians and Gynecologists. He has been recognized with several awards and honors, including being named a top doctor for outstanding patient care. Dr. Ferriss’ passion for getting to know each of his patients’ values and personal treatment goals and empowering them to be active participants in their treatment defines his approach to patient care. Dr. Ferriss has special interest in supporting his patients through the entire arc of their cancer care from diagnosis to surgery, chemotherapy, and survivorship and palliative care. Videos Dr. Stuart FerrissGynecologic Oncologist Contact for Research Inquiries 600 N. Wolfe St Phipps 281 Baltimore, MD 21287 Research Summary Dr. Ferriss’ research currently focuses on increasing the diversity of patients recruited to clinical trials by understanding the factors and circumstances that prevent some patients from participating. He is also focused on innovations in surgical and clinical education. Dr. Ferriss is rated as an Advanced provider by MediFind in the treatment of Melanoma. His top areas of expertise are Neuroendocrine Carcinoma of the Cervix, Cervical Cancer, Ovarian Cancer, Oophorectomy, and Lymphadenectomy.

Dr. Grant Anhalt is a professor of dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include autoimmune skin diseases and dermatoimmunology. Dr. Anhalt serves as the director of the Dermatoimmunology Laboratory at the Johns Hopkins School of Medicine. He received his undergraduate degree and his M.D. from the University of Manitoba. He completed a residency in internal medicine at the Health Sciences Center in Winnipeg, Canada and a residency in dermatology at the University of Michigan. He performed a fellowship in immunodermatology at the University of Michigan Medical Center. Dr. Anhalt joined the Johns Hopkins faculty in 1982. He was interim chair of the Department of Dermatology from 1996 to 2001. His research interests include autoimmunity, bullous skin diseases and pemphigus and pemphigoid. Dr. Anhalt serves on the medical advisory board for the International Pemphigus & Pemphigoid Foundation. He has been recognized as a top doctor in the Washington Post Magazine, Baltimore Magazine and Castle Connolly Guide. He is a member of several professional organizations, including the American Academy of Dermatology, American Dermatologic Association and American Society for Clinical Investigation. CV http://www.hopkinsmedicine.org/dermatology/our_experts/CV/Anhalt_CV_2014.docx. Dr. Anhalt is rated as an Advanced provider by MediFind in the treatment of Melanoma. His top areas of expertise are Pemphigus Vulgaris, Pemphigus, Pemphigus Foliaceus, and Bullous Pemphigoid.

Dr. Sima Rozati is an Assistant Professor of Dermatology at the Johns Hopkins University School of Medicine. She specializes in medical dermatology, cutaneous lymphoma, and supportive oncodermatology. She received her medical degree from the Shahid Beheshti University of Medical Sciences in Tehran. After completing her internal medicine residency at the Cleveland Clinic, she completed a research fellowship and PhD in cutaneous lymphoma at the University Hospital of Zürich in Switzerland. She returned to the U.S. where she completed cutaneous lymphoma fellowship, under the mentorship of Dr. Youn Kim, followed by dermatology residency at Stanford University School of Medicine in California. In a multidisciplinary environment, Dr. Rozati aims to provide excellent care to patients with cutaneous lymphoma and cancer whom are experiencing cutaneous adverse events from targeted therapies, immune- and chemotherapies. Dr. Rozati’s research interest focuses on cutaneous lymphoma, understanding the biology of this heterogeneous group of malignancies by analyzing the mutational and epigenetic landscape. Her translational research efforts is directed to investigate novel targeted and immunotherapeutic for cutaneous T cell lymphoma. She is a member of different professional organizations, including the American Academy of Dermatology and Woman’s dermatologic Society. Dr. Rozati is rated as an Advanced provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, Mycosis Fungoides, and Localized Scleroderma.

Daniel Synkowski is a Dermatologist in Baltimore, Maryland. Dr. Synkowski is rated as an Advanced provider by MediFind in the treatment of Melanoma. His top areas of expertise are Hidradenitis Suppurativa, Melanoma, Actinic Keratosis, and Warts.

Chao Yang is a Dermatologist in Baltimore, Maryland. Dr. Yang is rated as an Advanced provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Pyle Disease, Autosomal Recessive Hypotrichosis, Familial Atypical Multiple Mole Melanoma Syndrome, and Leg or Foot Amputation.

Charles Balch is a General Surgeon in Baltimore, Maryland. Dr. Balch is rated as an Advanced provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma and Breast Cancer.

Dr. Fisher is an associate professor of plastic surgery in the Johns Hopkins Department of Plastic Surgery. His areas of clinical expertise include burn surgery, burn reconstruction, craniofacial surgery, and reconstructive microsurgery. He serves as the Director of the Johns Hopkins Bayview Adult Burn Center. Committed to acute and reconstructive burn care of the highest quality, Dr. Fisher completed extensive training at multiple leading centers. These included a Burn Fellowship at the Shriners Hospital for Burns in Galveston, a Plastic Surgery Residency at Duke University, a Craniofacial Fellowship at the Hospital for Sick Children in Toronto, and a research fellowship at Harvard. Throughout his career Dr. Fisher has brought the full breadth and depth of his training to care for patients with the most complex injuries and deformities. From 2014 to 2022 he was on the faculty of the University of Iowa where he served in the burn unit, led the craniofacial team, and served the hand trauma team. Recognizing that complex injuries need coordinated care, he developed the Complex Face Group at Iowa to coordinate multiple specialty collaboration. Burns cause disfigurement, disability, and death particularly among the poor in the US and across the globe. Dr. Fisher’s research interests include improving prevention wherever burns happen, improving acute and reconstructive outcomes, and strengthening healthcare systems in the US and abroad in the face of burn and other disasters. His research interests also include wound healing and scar for burns and trauma. He has been a national and international leader in burn care. He founded and chaired the American Burn Association Committee on Reconstruction. He also founded and continues to lead the ABA series of burn reconstruction courses. He is frequently invited to speak internationally and serves actively in burn-related humanitarian agencies. Throughout his career, Dr. Fisher has emphasized the importance of a holistic approach seeking the restoration of not only physical health, but emotional recovery, social connection, and work reintegration of his patients. Dr. Fisher is rated as an Advanced provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Neurofibromatosis, Neurofibromatosis Type 1 (NF1), Osteotomy, and Bone Graft.